Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Ascentage Pharma Group Corp / Equity Capital Markets

<p>Ascentage Pharma is pre-marketing the USD 200 - 300 million IPO to list in Hong Kong. In our previous insight, we highlight the company's key product pipeline and its shareholders. We are of the view that the company is still in the early stages of development hence it has significant R&amp;D risks relative to other biotech listings in Hong Kong.</p>
<p>In this insight, we will provide an update on new information available from both the approved prospectus and the progress of its clinical trials. We will also do a more thorough comparison between its core product HQP1351 and the benchmark product ponatinib. We will also discuss the background of ponatinib and the challenges for HQP1351 for it to become a billion-dollar drug.</p>
<h2>Our previous coverage on Ascentage Pharma</h2>
<ul>
<li><a href="https://www.smartkarma.com/insights/ascentage-pharma-ipo-too-early-for-an-ipo" target="_blank">Ascentage Pharma (亚盛医药) IPO: Too Early for an IPO</a></li>
</ul>

Ascentage Pharma is pre-marketing the USD 200 - 300 million IPO to list in Hong Kong. In our previous insight, we highlight the company's key product pipeline and its shareholders. We are of the view that the company is still in the early stages of development hence it has significant R&amp;D risks relative to other biotech listings in Hong Kong.
In this insight, we will provide an update on new information available from both the approved prospectus and the progress of its clinical trials. We will also do a more thorough comparison between its core product HQP1351 and the benchmark product ponatinib. We will also discuss the background of ponatinib and the challenges for HQP1351 for it to become a billion-dollar drug.
Our previous coverage on Ascentage Pharma

Ascentage Pharma (亚盛医药) IPO: Too Early for an IPO


Ascentage Pharma (亚盛医药) IPO: Updates and Thoughts on HQP1351 (3rd Gen Bcr-Abl TKI)

<p>Ascentage Pharma, a China-based biotech company, filed an application to list on the Hong Kong Stock Exchange. In this insight, we will cover the following topics:</p>
<ul class="">
<li>Ascentage Pharma's drug candidate pipeline and key drug candidates. </li>
<li>The addressable market for key products.</li>
<li>Our read on the company's founders and investors.</li>
</ul>
<hr>
<div>
<h2>Our coverage on biotech listing</h2>
<ul>
<li><a href="https://www.smartkarma.com/insights/junshi-bioscience-ipo-thoughts-on-valuation-part-2" target="_blank">Junshi Bioscience (君实医药) IPO: Thoughts on Valuation (Part 2)</a></li>
<li><a href="https://www.smartkarma.com/insights/junshi-bioscience-ipo-early-in-application-but-behind-in-key-indications-part-1" target="_blank">Junshi Bioscience (君实医药) IPO: Early in Application but Behind in Key Indications (Part 1)</a></li>
<li><a href="https://www.smartkarma.com/insights/cansino-biologics-ipo-promising-pre-clinical-results-but-vaccine-scandal-weighs-part-1" target="_blank">CanSino Biologics (康希诺) IPO: Promising Pre-Clinical Results but Vaccine Scandal Weighs (Part 1)</a></li>
</ul>
</div>
<ul>
<li><a href="https://www.smartkarma.com/insights/aobiome-therapeutics-ipo-hope-for-natural-therapeutic-treatment" target="_blank">AOBiome Therapeutics IPO: Hope for Natural Therapeutic Treatment</a></li>
<li><a href="https://www.smartkarma.com/insights/stealth-biotherapeutics-ipo-cure-the-symptoms-but-not-the-cause-part-1" target="_blank">Stealth Biotherapeutics IPO: Cure the Symptoms but Not the Cause (Part 1)</a></li>
<li><a href="https://www.smartkarma.com/insights/innovent-biologics-ipo-pricing-the-pd-1-and-biosimilars-competition-part-2" target="_blank">Innovent Biologics (信达生物) IPO: Pricing the PD-1 and Biosimilars Competition (Part 2)</a></li>
<li><a href="https://www.smartkarma.com/insights/innovent-biologics-ipo-a-major-pd-1-mab-competitor-might-have-just-emerged-part-1" target="_blank">Innovent Biologics (信达生物) IPO: A Major PD-1 MAb Competitor Might Have Just Emerged (Part 1)</a></li>
<li><a href="https://www.smartkarma.com/insights/micurx-pharma-ipo-betting-on-single-drug-in-the-not-so-attractive-antibiotic-segment" target="_blank">MicuRx Pharma (盟科医药) IPO: Betting on Single Drug in the Not so Attractive Antibiotic Segment</a></li>
<li><a href="https://www.smartkarma.com/insights/hua-medicine-ipo-thoughts-on-valuation" target="_blank">Hua Medicine (华领医药) IPO: Thoughts on Valuation</a></li>
<li><a href="https://www.smartkarma.com/insights/hua-medicine-ipo-reviving-roche-s-failed-attempt" target="_blank">Hua Medicine (华领医药) IPO: Reviving Roche’s Failed Attempt?</a></li>
<li><a href="https://www.smartkarma.com/insights/beigene-ipo-dual-listing-with-upside-capped-in-the-near-term" target="_blank">BeiGene (百济神州) IPO: Dual-Listing with Upside Capped in the Near Term</a></li>
<li><a href="https://www.smartkarma.com/insights/ascletis-pharma-ipo-valuation-not-justified-by-ganovo-and-ravidasvir-npv-part-3" target="_blank">Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)</a></li>
<li><a href="https://www.smartkarma.com/insights/ascletis-pharma-ipo-three-valuation-risk-factors-part-2" target="_blank">Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)</a></li>
<li><a href="https://www.smartkarma.com/insights/ascletis-pharma-ipo-emerging-player-in-the-crowded-hcv-drug-market" target="_blank">Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market</a></li>
<li><a href="https://www.smartkarma.com/insights/china-isotope-radiation-ipo-oligopoly-visible-growth-and-high-barrier-to-entry" target="_blank">China Isotope &amp; Radiation IPO: Oligopoly, Visible Growth and High Barrier to Entry</a></li>
<li><a href="https://www.smartkarma.com/insights/zai-lab-ipo-thoughts-on-valuation-risks-and-upsides-part-2" target="_blank">Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)</a></li>
<li><a href="https://www.smartkarma.com/insights/zai-lab-ipo-experienced-team-promising-in-licensing-drug-pipeline-part-1" target="_blank">Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)</a></li>
</ul>

Ascentage Pharma, a China-based biotech company, filed an application to list on the Hong Kong Stock Exchange. In this insight, we will cover the following topics:

Ascentage Pharma's drug candidate pipeline and key drug candidates. 
The addressable market for key products.
Our read on the company's founders and investors.



Our coverage on biotech listing

Junshi Bioscience (君实医药) IPO: Thoughts on Valuation (Part 2)
Junshi Bioscience (君实医药) IPO: Early in Application but Behind in Key Indications (Part 1)
CanSino Biologics (康希诺) IPO: Promising Pre-Clinical Results but Vaccine Scandal Weighs (Part 1)



AOBiome Therapeutics IPO: Hope for Natural Therapeutic Treatment
Stealth Biotherapeutics IPO: Cure the Symptoms but Not the Cause (Part 1)
Innovent Biologics (信达生物) IPO: Pricing the PD-1 and Biosimilars Competition (Part 2)
Innovent Biologics (信达生物) IPO: A Major PD-1 MAb Competitor Might Have Just Emerged (Part 1)
MicuRx Pharma (盟科医药) IPO: Betting on Single Drug in the Not so Attractive Antibiotic Segment
Hua Medicine (华领医药) IPO: Thoughts on Valuation
Hua Medicine (华领医药) IPO: Reviving Roche’s Failed Attempt?
BeiGene (百济神州) IPO: Dual-Listing with Upside Capped in the Near Term
Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)
Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)
Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market
China Isotope &amp; Radiation IPO: Oligopoly, Visible Growth and High Barrier to Entry
Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)
Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)


Ascentage Pharma (亚盛医药) IPO: Too Early for an IPO

China

Ascentage Pharma Group International operates as a clinical-stage biotechnology company. The Company develops novel therapies for cancers, hepatitis B virus, age-related diseases, and more. Ascentage Pharma Group International conducts businesses in China, the United States, and other countries.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ascentage Pharma Group Corp (6855 HK)

Ascentage Pharma (亚盛医药) IPO: Updates and Thoughts on HQP1351 (3rd Gen Bcr-Abl TKI)

Ascentage Pharma is pre-marketing the USD 200 - 300 million IPO to list in Hong Kong. In our previous insight, we highlight the company's key...

Ke Yan, CFA, FRM

Ascentage Pharma (亚盛医药) IPO: Too Early for an IPO

Ascentage Pharma, a China-based biotech company, filed an application to list on the Hong Kong Stock Exchange. In this insight, we will cover the...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)